Evaluation of Azithromycin-Bicarbonate against Multidrug-Resistant Pathogens in Topical Murine Models of Infection
- 10 December 2025
- journal article
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 12 (1) , 128-138
Abstract
Multidrug-resistant pulmonary infections pose significant therapeutic challenges as treatment options continue to dwindle in the face of rising antimicrobial resistance. Similar challenges arise in the management of wound infections such as those resulting from burn and blast injuries, where resistant pathogens severely limit treatment options. These wounds are further complicated by high microbial loads that exacerbate tissue damage, delay healing, and increase the risk of systemic infection. The escalating threat of antimicrobial resistance highlights the urgent need for innovative therapeutic strategies. This study evaluates the therapeutic potential of a novel topical formulation, azithromycin-bicarbonate (AZM-BIC), for addressing drug-resistant infections in both pulmonary and wound settings. Using murine models of infection in bicarbonate-depleted environments, including lung, blast injury, and burn wound models, topical administration of AZM-BIC enabled the localized delivery of therapeutic concentrations of bicarbonate. In the pulmonary model, AZM-BIC significantly reduced the bacterial burden. In vitro and ex vivo studies revealed AZM-BIC's ability to inhibit biofilm formation, a critical factor in managing chronic infections. In wound infection models, AZM-BIC reduced the bacterial burden and enhanced wound healing. These findings establish AZM-BIC as a promising therapeutic approach, offering a targeted, effective solution for pulmonary infection management and wound care amid the growing threat of antimicrobial resistance. Furthermore, given that azithromycin is a well-established antibiotic and bicarbonate is a physiological component that is safe and well-tolerated, AZM-BIC represents a readily translatable strategy for clinical implementation.Keywords
Funding Information
- Canadian Institutes of Health Research (PJT 186281)
- Canada Research Chairs
- National Institute of General Medical Sciences (R35 GM137828)
- Southern Ontario Pharmaceutical and Health Innovation Ecosystem
This publication has 50 references indexed in Scilit:
- Drug-impregnated, pressurized gas expanded liquid-processed alginate hydrogel scaffolds for accelerated burn wound healingActa Biomaterialia, 2020
- Safety, Tolerability, and Effects of Sodium Bicarbonate Inhalation in Cystic FibrosisClinical Drug Investigation, 2019
- Surprising synergy of dual translation inhibition vs. Acinetobacter baumannii and other multidrug-resistant bacterial pathogensEBioMedicine, 2019
- Skin and Soft Tissue Models for Acinetobacter baumannii Infection2019
- Inhalation of Macrolides: A Novel Approach to Treatment of Pulmonary Infections2014
- Cause of death and correlation with autopsy findings in burns patientsBurns, 2013
- Prevalence of multidrug-resistant organisms recovered at a military burn centerBurns, 2010
- Effects of three different topical antibacterial dressings on Acinetobacter baumannii-contaminated full-thickness burns in ratsBurns, 2009
- Multidrug-resistant Organisms in Military Wounds from Iraq and AfghanistanClinical Orthopaedics and Related Research, 2008
- Growing and Analyzing Static BiofilmsCurrent Protocols in Microbiology, 2005